Synageva gains orphan-drug status for enzyme-replacement therapy

07/7/2010 | Boston Globe (tiered subscription model), The

The FDA granted orphan-drug designation to SBC-102, Synageva BioPharma's enzyme-replacement therapy. The drug candidate is being developed as a treatment for lysosomal acid lipase deficiency, a rare disorder for which there is no approved treatment.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
Springfield, OR
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA